OncoSec Medical Expands Legal Team, Appoints Sheela Mohan-Peterson as General Counsel and Corporate Secretary
Former Senior Patent Counsel at Merck & Co., Inc. to Oversee Global Legal Strategy
SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has appointed Sheela Mohan-Peterson, J.D., M.S. to the position of General Counsel and Corporate Secretary. In this newly created role, she will be responsible for leading the Company’s global legal strategy and guiding the continued expansion of its intellectual property portfolio. Ms. Mohan-Peterson will be supported by an experienced internal legal team that includes legal associate and paralegal positions.
Punit Dhillon, President and CEO, said, “Sheela will be leading our expanded legal department during a pivotal moment for the Company. Her extensive legal expertise and strategic leadership experience will allow us to aggressively pursue new intellectual property and support the ongoing expansion of our R&D and preclinical activities, as well as take the lead on negotiating several business development opportunities.”
Ms. Mohan-Peterson has spent more than 27 years working in the pharmaceutical and biotech industries, most recently as a Senior Patent Counsel with Merck & Co., Inc. She received her bachelor’s degree in biology from Washington University in St. Louis, and her master’s degree in molecular biology from Rutgers University. Ms. Mohan-Peterson began her career in 1986 as a scientist in the Tumor Biology department of Schering-Plough Research Institute in Bloomfield, New Jersey. In 1991, she transferred to the Human Immunology department at DNAX Research Institute, a subsidiary of Schering-Plough, located in Palo Alto, California. After graduating from law school in 1997, she began her career as a patent attorney at Incyte Genomics in Palo Alto, and then as a patent counsel at Roche Bioscience, also in Palo Alto. In 2000, she returned to DNAX as a senior patent counsel and remained there for several years after a merger with Merck.
“I am very excited to be leading OncoSec’s legal department,” said Ms. Mohan-Peterson. “In my new role, one of my major goals will be to strengthen and expand OncoSec’s intellectual property, which will establish a strong foundation to propel the company to great success in the future.”
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical’s core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma, conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination therapeutic approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Source: OncoSec Medical Inc.
Released September 17, 2014